Liver fat: the NAFLD evidence

The promising second act: reducing liver fat, still off-label

The best-supported use beyond the label is fatty liver in HIV. Two randomized trials show tesamorelin meaningfully reduces liver fat, and paired biopsies in the second trial found less fibrosis progression, all through the same visceral-fat mechanism.

This unit covers the pathobiology of HIV-associated fatty liver, the Stanley 2014 and 2019 trials, the visceral-to-liver mechanism, and why strong data in a narrow population is still not the same as an approved indication.